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ABSTRACT
Inhaled therapy is the cornerstone of asthma
management in that it optimizes the delivery of
the medication to the site of action. The
effectiveness of inhaled therapy is affected by
the correct choice of the device and proper
inhalation technique. In fact, this influences
the drug delivery and distribution along the
bronchial tree, including the most peripheral
airways. In this context, accumulating evidence
supports the contribution of small airways in
asthma, and these have become an important
target of treatment. In reality, the ‘‘ideal
inhaler’’ does not exist, and not all inhalers
are the same. Advances in technology has
highlighted these differences, and have led to
the design of new devices and the development
of formulations characterized by extrafine
particles that facilitate the distribution and
deposition of the drug particles along the
respiratory tract. In addition, efforts have been
made to implement adherence to chronic
treatment, which translates into clinical
benefit. Taken together, the optimal control of
asthma depends on the drug that is selected, the
device that is employed and the removal of
factors that reduce patient’s adherence to
therapy.
Keywords: Adherence; Asthma control;
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INTRODUCTION: ASTHMA
CONTROL AND ITS OBSTACLES
Current asthma management guidelines
emphasize the importance of disease control
[1]. Despite the availability of effective drug
therapies and relevant advances in inhaler
technology, real-life data clearly show that the
level of asthma control is still unacceptably low
[2]. Asthma control consists of two domains:
symptom control and management of future
risk of adverse outcomes [1]. Inhaled therapy is
the cornerstone of asthma management, in that
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it optimizes the delivery of the medication to
the site of action as opposed to systemic
administration of the drug [1]. In addition to
the proper choice of the active drug, the
selection of the correct device plays a crucial
role in achieving optimal control and
preventing future risk. The selection of the
inhaler device should be primarily based on
the specific needs of the individual patients,
bearing in mind that the ‘‘ideal’’ inhaler does
not exist in real life, but is rather the ‘‘right’’
inhaler for the ‘‘right’’ patient.
This review provides a critical analysis of
factors related to both drug formulation and
device features that can have an impact on
asthma management. The efficacy of a
treatment is linked also to patient adherence,
and developments in drugs and devices over the
past decades have consistently contributed to
improve adherence to inhaled treatment and,
possibly, drug delivery to the entire bronchial
tree [3, 4]. It is known that low drug deposition
and device mishandling are associated with
poor disease control and increased
consumption of healthcare resources [5]. All
these aspects will be discussed to better
understanding how these factors should be
considered as part of the decision-making
process, leading to the choice of an inhaler
device.
THE PATIENT AND THE PHYSICIAN
Misuse of an inhaler is common in clinical
practice, and proper training of patients and
physicians is important to ensure the correct
use of the device. Patient technique has a large
impact on the amount of active drug delivered
to the site of action and, therefore, on the
efficacy and disease control [3]. A study by
Harnett et al. [6] demonstrated the importance
of educating and formally assessing inhaler
technique in patients with asthma as part of
their ongoing clinical review. The first step to
ensure proper management of the disease is
therefore to educate patients in inhaler
technique. Patient satisfaction is also an
important aspect, as it significantly correlates
with better outcomes [3]. On the other hand,
little attention is given to the training of the
physicians, and to the patient-to-physician
education interaction. Current guidelines
recommend that physicians follow adherence
management strategies; however, evidence for
these interventions is weak [1]. It is estimated
that 39–67% of nurses, doctors, and respiratory
therapists are not able to adequately train
patients on the correct use of the device [3].
Perhaps, physicians’ choice of the device is also
based on how confident he/she feels in
explaining the use of the inhaler to their
patients. This has clinical implications in daily
practice. In addition, the interaction between
patients and physicians often does not
incorporate any agreement on the choice of
the device, and the level of compliance with the
prescribed treatment is not routinely assessed,
and this is becoming a challenge in primary
care. Healthcare providers cannot assume that
correct inhaler use is self-evident [7], and
cannot rely on patients following instructions
provided in inhaler packages [8]. Patients may
misreport non-adherence, or avoid
embarrassing questions on the use of the
inhaler, to avoid disappointing their
physicians who may not actively inquire about
it [3]. It is logical to expect that this
phenomenon would invariably lead to the
progressive loss of treatment efficacy.
In this scenario, the value of other
healthcare professionals has been increasingly
recognized to support (or replace) physicians.
Certified Respiratory Educators (CREs) have
Adv Ther
been demonstrated to properly manage chronic
respiratory patients as effectively as specialists
[9]. CREs such as nurses, respiratory therapists,
physiotherapists and pharmacists supply
services traditionally delivered by physicians.
This may include patient education, with an
emphasis on patient self-management and
instruction in proper inhaler technique [10].
DRUG FORMULATION AND DEVICE
CHARACTERISTICS
Inhalation technique is critical to achieve
treatment success and differs substantially
between inhaler devices [11]. Four different
classes of device are currently available for
pulmonary drug delivery: pressurized metered
dose inhalers (pMDIs), dry powder inhalers
(DPIs), soft mist inhalers (SMIs) and nebulizers.
All these devices have both advantages and
limitations [11]. As a general rule, pMDIs
require good coordination, which is not always
obtained in obstructed subjects. To overcome
this limitation, the use of a spacer with pMDIs is
often recommended, especially for patients with
known or suspected poor coordination (e.g.,
children and the elderly). Spacers reduce the
risk of cold-Freon effect and the need for perfect
hand–breath coordination [11]. DPIs require a
turbulent flow of air to transform the metered
powder formulation combined with a lactose
carrier into disaggregated particles. For DPIs, the
inhalation flow must be maintained from the
start of inhalation for anextendedperiodof time,
andpatients are required tobreathe asdeeply and
forcefully as possible to allow the coarse particles
combined with a lactose carrier to disaggregate.
In reality, patients have a variable degree of
airflow limitation, with consequently lower
inspiratory flows compared to healthy subjects
[12]. Thismay affect the distributionof the active
compounds in the lung [12]. As mentioned
earlier, the ‘‘ideal inhaler’’ does not exist. Not all
inhalers are the same, and advances in
technology have highlighted their differences.
This is aparadox, since the scopesof thesedevices
are to simplify the steps of usage, and to increase
the amount of drug deposited in the lungs.
Nowadays, it is plausible to assume that
switching from one device to another may have
dramatic consequences on loss of asthma
control.
Several factors play a primary role in
determining the efficacy of the drug deposition
in the large and small airways, and are related to
the characteristics of both the drug formulation
and thedevice [13]. The ideal device should allow
high levels of drug deposition in the lung while
minimizing the deposition outside the lung. To
accomplish this, the inhaler should incorporate
two main characteristics. First, ease of use and
feedback systems to optimize the patient’s
technique/coordination and to reassure them
that the drug has been administered. Secondly, a
uniform and consistent deposition of the drug
between doses. A consensus statement by the
task force of the European Respiratory Society
(ERS) and the International Society for Aerosols
in Medicine (ISAM) provides clear
recommendations for choosing the best aerosol
delivery device based on a patient’s actuation–
inhalation coordination, level of inspiratoryflow
and clinical conditions [14]. For example, some
inhalers require strong inspiratory force, which
maynot be possible in emergency situations or in
children and elderly.
ARE ALL INHALERS THE SAME?
Over the years, inhalers have undergone
improvements in terms of technical design.
Special efforts have been made to improve the
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relationship between inspiratory flow rate and
actuation, as well as to the characteristics of
propellant and reproducibility of the dose
between inhalations. pMDIs are all similar in
their mode of use, but they invariably differ in
terms of homogeneity of the concentration of
the drug and, consequently, the emission of a
constant amount of drug between doses. In
suspension formulations, the active drug is not
soluble in the propellant, thus remaining in
solid powder form in the container. It follows
that formulations in suspension must be shaken
until uniformity of distribution within the
canister is reached before use. In clinical
settings, this is one of the most common
critical errors [5]. Switching to solution
formulations overcomes the issue of non-
uniform distribution and can allow extrafine
drug delivery, reducing the particle size of
emitted aerosol and, thereby, allowing deeper
penetration in the bronchial tree [15].
Functional changes that occur in the smallest
airways have been linked to features of severe
uncontrolled disease [16, 17], so it is therefore
plausible to assume that the extrafine
formulations that act on peripheral airway
abnormalities [18–20] could also improve
asthma control, as demonstrated by
randomized trials [21] and real-life
observational studies [22, 23]. Breath-activated
pMDI (BA-pMDI) devices are also available,
which release the drug when inhalation
triggers the metered dose inhaler. Currently,
there is only one commercially available soft
mist inhaler: Respimat" (Boehringer Ingelheim,
Ingelheim am Rhein, Germany). This inhaler
atomizes the drug solution using mechanical
energy imparted by a spring, producing a fine,
slow-moving mist, with less deposition in the
mouth and throat and relatively higher lung
deposition.
Three types of DPIs are available with
different handling instructions: single dose
[Breezhaler" (Novartis International AG, Basel,
Switzerland), HandiHaler" (Boehringer
Ingelheim GmbH, Ingelheim am Rhein,
Germany), Aerolizer" (Novartis International
AG, Basel, Switzerland)], multiple dose
[Diskus" (GlaxoSmithKline, Uxbridge, UK.
Durable Sidestream)] and reservoir
[Turbuhaler" (AstraZeneca Plc, London UK),
NEXThaler" (Chiesi Farmaceutica SPA, Parma,
Italy)]. DPIs contain powdered drug that is
dispersed into particles after activation by an
inspiratory maneuver. Unlike pMDIs, DPIs
differ from one to another, and the required
steps to activate them may vary significantly
[14]. The major advantage of DPIs is that since
they are breath actuated, they do not need any
coordination between activation and inhalation
[14]. The major disadvantage is the fact that the
powders contained in the DPI can be
hygroscopic, and, for this reason, they can
attract humidity and stick to the nozzle walls
[14]. In addition, an adequate inspiratory flow is
required to activate the device. Each DPI offers a
different resistance to inhalation and needs a
specific threshold inspiratory flow to accurately
deliver the dose [14]. Recent devices have been
designed with the aim of simplifying inhalation
maneuvers. In this regard, the NEXThaler,
Ellipta" (GlaxoSmithKline, Uxbridge, UK) and
Spiromax" (Teva Pharma B.V., Utrecht, The
Netherlands) devices are novel, intuitively
designed DPIs conceived for straightforward
open–inhale–close operation that ensures ease
of use. In comparison to the other DPIs
available, the NEXThaler is able to ensure a
consistent full-dose delivery independently
from the patient’s inhalation profile. Once the
breath-actuated mechanism (BAM) is activated,
the NEXThaler guarantees, at each inhalation,
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that the full therapeutic dose is delivered [24].
Therefore, by checking the dose counter both
patients and doctors are able to understand if
the drug has been effectively inhaled. The
NEXThaler is the first DPI that has been
developed to generate extrafine particles [4].
The currently available inhaled
corticosteroid/long-acting beta agonist fixed
combinations delivered through DPIs are not
able to dispense extrafine shots with a mass
median aerodynamic diameter (MMAD) lower
than 2 lm [19]. The extrafine beclometasone
dipropionate/formoterol (BDP/F) fixed
combination therefore represents the only
extrafine combination in both pMDI and DPI
formulations developed so far (Fig. 1).
Particle size is an important feature to be
considered when comparing different devices
since the particle dimension influences drug
deposition in the lungs [4]. Bigger particles have
a higher kinetic energy and, for this reason,
they impact on the airway walls, while small
particles can also reach the peripheral airways.
Therefore, lung deposition of a drug
formulation depends on the MMAD, which is
the droplet size at which half of the mass of the
aerosol is contained in smaller droplets and half
in larger droplets. It also depends on the fine
particle fraction (FPF), meaning the percentage
of particles\5 lm in diameter [4]. Generally,
FPF is proportional to the fraction of emitted
dose reaching the lung. Particles with an
MMAD[5 lm tend to accumulate in the
oropharynx, while particles with an MMAD
between 1 and 5 lm tend to reach the airways
at different levels according to their dimensions
[4]. Obviously, the smaller the particles
(between 1 and 5 lm), the higher the
proportion of particles reaching the peripheral
airways [25]. The advantages in terms of asthma
control with the use of extrafine formulations
have been shown in real-life studies [22, 23, 26–
29]. These findings obtained in real-life studies
may benefit from further confirmation in
randomized controlled trials.
Poor adherence with asthma management
plans and treatment regimens has been
associated with poor disease control [30] and
increased risk of hospital admission [31]. Patient
and parental reports of adherence are often
inaccurate [32], and also physicians’ subjective
impressions may be equally unreliable [33].
Monitoring devices characterized by smart
technology should ideally be able to monitor
adherence covertly, accurately record the time
that each dose was taken, store data over a
reasonable time period, detect multiple
successive actuations and provide access to
data that may be downloaded to a personal
computer [34]. It is logical to imply that ‘‘smart
technology’’ would improve patient adherence,
with a possible positive impact on asthma
control. This needs to be proven in large
population-based studies.
Fig. 1 Dimensions of the particles of the inhaled fixed
combination formulations in terms of mass median
aerodynamic diameter (MMAD). BDP/F beclometasone
dipropionate/formoterol, BUD/F budesonide/formoterol,
DPI dry powder inhaler, FP/Salm fluticasone propionate/
salmeterol, FP/F fluticasone propionate/formoterol, pMDI
pressurized metered dose inhaler
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HOW DOES THE INHALER IMPROVE
ADHERENCE TO TREATMENT?
The challenge of patients not following medical
advice dates back to the 4th century BC, when
Hippocrates observed that some patients were
not taking their prescribed treatments [35].
Adherence is usually dichotomized for
research purposes and is often defined as
missing at least 20% of the medication. This
cutoff has been demonstrated to predict
subsequent hospitalization across several
chronic conditions [36]. Adherence to therapy
is likely to be influenced by patients’ attitudes
and their experience in using the device. If
patients feel that treatment is not working,
adherence is likely to be poor with
consequently reduced efficacy of treatment
[37]. The availability of several inhaler devices
may also confuse the patient. Switching
between different inhalers negatively affects
care, as inhaler classes and brands differ in
design (particularly DPIs) and each device has
unique required steps and inhalation
techniques [38]. Booker showed that half of
asthmatic patients were reluctant to change
their current DPI to an alternative device, and
the majority reported concerns about being
trained in the use of a new device or
confusion around the need for change [39].
Regular training sessions should be provided at
each visit and patients should be encouraged to
bring their inhalers to provide demonstration of
competence in inhalation technique.
The clinical variability of asthma makes the
disease particularly prone to erratic adherence.
Patients usually tend to reduce adherence during
the asymptomatic phases of their disease.
Unintentional adherence often occurs when,
for example, a patient does not understand the
proper technique for inhaler use. In this regard,
improper use of inhaler devices has been shown
to be associated with loss of asthma control [40,
41], presumably contributing to increased
disease burden for caregivers and society.
Customized patient-friendly treatment that
anticipates and accommodates usual behavior
and addresses conscious and unconscious
medication beliefs is more likely to achieve the
desired goal of disease control [42].
CONCLUSION
Optimal control of asthma depends on the drug
that is selected, the device that is employed and
the removal of factors that reduce patients’
adherence to therapy. In this regard, while
international guidelines recommend careful
attention to the choice of the device and the
education to patients, a consensus is lacking on
how to properly choose appropriate inhaler
devices. This implies that factors that are not
clinically relevant may, however, influence the
choice of the optimal inhaler device. Simplistic
‘‘one size fits all’’ approaches are not the solution.
Rather, a personalized selection of the device
based on patient preferences and perceptions
should be encouraged and implemented in
clinical practice. Most probably, differences in
efficacy become trivial, or even disappear, when
the device is used with the proper inhalation
technique. The key issue in asthmamanagement
is therefore to train patients and to verify the
correct inhalation maneuver.
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